Should I buy or sell Insulet stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PODD shares. View PODD analyst ratings or view top-rated stocks .

What is Insulet's stock price target for 2024?

16 analysts have issued 12-month price targets for Insulet's shares. Their PODD share price targets range from $162.00 to $350.00. On average, they predict the company's stock price to reach $250.40 in the next year. This suggests a possible upside of 27.3% from the stock's current price. View analysts price targets for PODD or view top-rated stocks among Wall Street analysts .

How have PODD shares performed in 2024?

Insulet's stock was trading at $216.98 at the beginning of the year. Since then, PODD stock has decreased by 9.4% and is now trading at $196.64. View the best growth stocks for 2024 here .

Are investors shorting Insulet?

Insulet saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 2,700,000 shares, a decline of 16.7% from the December 31st total of 3,240,000 shares. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is currently 2.4 days. View Insulet's Short Interest .

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our PODD earnings forecast .

How can I listen to Insulet's earnings call?

Insulet will be holding an earnings conference call on Thursday, February 22nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings data on Thursday, May, 4th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.14. The medical instruments supplier earned $358.10 million during the quarter, compared to analyst estimates of $330.21 million. Insulet had a net margin of 7.71% and a trailing twelve-month return on equity of 23.98%. The business's revenue was up 21.2% on a year-over-year basis. During the same period last year, the firm earned $0.40 earnings per share.

What ETFs hold Insulet's stock?

ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include Fidelity Digital Health ETF (FDHT) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , Goldman Sachs Future Health Care Equity ETF (GDOC) , Invesco Focused Discovery Growth ETF (IVDG) , Harbor Health Care ETF (MEDI) , Fidelity Disruptive Medicine ETF (FMED) , VictoryShares Nasdaq Next 50 ETF (QQQN) and Nuveen ESG Mid-Cap Growth ETF (NUMG) .

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com . Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA) , DexCom (DXCM) , Netflix (NFLX) , Alibaba Group (BABA) , Tesla (TSLA) , Block (SQ) , Walt Disney (DIS) , Salesforce (CRM) , Roku (ROKU) and Trade Desk (TTD) .

Who are Insulet's major shareholders?

Insulet's stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (1.74%), Charles Schwab Investment Management Inc. (0.58%), Fisher Asset Management LLC (0.49%), abrdn plc (0.44%), Ownership Capital B.V. (0.40%) and Swiss National Bank (0.31%). Insiders that own company stock include Bret Christensen , Charles Alpuche , Dan Manea , James Hollingshead , John A Fallon , Luciana Borio , Michael P Spears , Prem Singh , Sally Crawford , Shacey Petrovic and Wayde D Mcmillan . View institutional ownership trends .

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PODD

Insulet (PODD) Stock Price, News & Analysis

$196.64

-2.11 (-1.06%)

(As of 02/8/2024 ET)

Compare

Today's Range: $194.89
▼
$198.06
50-Day Range: $189.30
▼
$221.42
52-Week Range: $125.82
▼
$335.91

Volume: 424,463 shs
Average Volume: 819,102 shs
Market Capitalization: $13.73 billion

P/E Ratio: 114.99
Dividend Yield: N/A
Price Target: $250.40

Get Insulet alerts:

Insulet MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.81 Rating Score
Upside/Downside: 27.3% Upside
$250.40 Price Target
Short Interest: Healthy
3.87% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.20
Upright™ Environmental Score
News Sentiment: 0.77
Based on 11 Articles This Week
Insider Trading: Selling Shares
$3.29 M Sold Last Quarter
Proj. Earnings Growth: 28.93%
From $1.97 to $2.54 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.85 out of 5 stars

Medical Sector

29th out of 911 stocks

Surgical & Medical Instruments Industry

3rd out of 91 stocks

3.4

Analyst's Opinion

Consensus Rating
Insulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $250.40, Insulet has a forecasted upside of 27.3% from its current price of $196.64.
Amount of Analyst Coverage
Insulet has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.87% of the outstanding shares of Insulet have been sold short.
Short Interest Ratio / Days to Cover
Insulet has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Insulet has recently decreased by 16.67%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Insulet does not currently pay a dividend.
Dividend Growth
Insulet does not have a long track record of dividend growth.

4.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Insulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.
Environmental Sustainability
The Environmental Impact score for Insulet is -1.20.

2.7

News and Social Media Coverage

News Sentiment
Insulet has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Insulet this week, compared to 8 articles on an average week.
Search Interest
Only 13 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,286,600.00 in company stock.
Percentage Held by Insiders
Only 0.90% of the stock of Insulet is held by insiders.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Insulet are expected to grow by 28.93% in the coming year, from $1.97 to $2.54 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Insulet is 114.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.28.
Price to Earnings Ratio vs. Sector
The P/E ratio of Insulet is 114.99, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 103.38.
Price to Earnings Growth Ratio
Insulet has a PEG Ratio of 2.21. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Insulet has a P/B Ratio of 28.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Insulet Stock (NASDAQ:PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

PODD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PODD Stock News Headlines

January 25, 2024 | marketbeat.com

5 top healthcare stocks for earnings growth in 2024 (PODD)

2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.

January 22, 2024 | marketbeat.com

MarketBeat ‘Stock of the Week’: Intuitive Surgical hits new highs (PODD)

With recent obesity drug fears proving to be overblown and equipment placements growing, expect ISRG to reward growth investors with plenty more record highs.

February 8, 2024 | DTI (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

January 8, 2024 | marketbeat.com

HCA Healthcare Rallies: Weight-loss drugs really a big threat? (PODD)

HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges.

February 8, 2024 | americanbankingnews.com

Insulet (NASDAQ:PODD) Price Target Raised to $208.00

February 7, 2024 | msn.com

Insulet gets CE Mark for Ominipod 5 with FreeStyle Libre 2 sensor

February 7, 2024 | finance.yahoo.com

Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor

February 3, 2024 | finance.yahoo.com

Why Insulet Corporation (NASDAQ:PODD) Looks Like A Quality Company

February 8, 2024 | The Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

February 3, 2024 | americanbankingnews.com

Brokerages Set Insulet Co. (NASDAQ:PODD) Price Target at $259.33

February 2, 2024 | msn.com

Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod

January 26, 2024 | msn.com

Insulet Secures Lower Interest Rates in Credit Agreement Amendment

January 22, 2024 | benzinga.com

Insulet Unusual Options Activity For January 22

January 18, 2024 | finance.yahoo.com

Insulet Announces Changes to Board of Directors with Retirements and New Appointments